NaseemaGangatMD

Instructor, Internal Medicine, Mayo Medical School

Dr. Gangat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2007 - 2010
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2004 - 2007
Aga Khan Medical CollegeClass of 2002

Actuate 1901: 9-ING-41 in Myelofibrosis Start of enrollment: 2020 Aug 20
Completed
Phase 2
Roles: Contact

PubMed

Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Naseema Gangat, Azeem Elbeih, Nour Ghosoun, Kristen McCullough, Fnu Aperna
American Journal of Hematology. 2024-12-13
1 citations
High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations.
Zhuoer Xie, Jenna Fernandez, Terra Lasho, Christy Finke, Michelle Amundson
Blood. 2024-12-05
1 citations
PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
Ayalew Tefferi, Saubia Fathima, Ali Khalid A Alsugair, Fnu Aperna, Anuya Natu
American Journal of Hematology. 2024-12-01

Journal Articles

MPL-Mutated Essential Thrombocythemia: A Morphologic Reappraisal
Naseema Gangat, Natasha Szuber, Rhett P Ketterling, Nature
Determinants of Long-Term Outcome in Type 1 Calreticulin-Mutated Myelofibrosis
Naseema Gangat, Natasha Szuber, Rhett P Ketterling, Nature